Literature DB >> 9324631

[Regression of retroperitoneal fibrosis by combination therapy with tamoxifen and steroids].

J Allendorff1, W Riegel, H Köhler.   

Abstract

BACKGROUND: Idiopathic retroperitoneal fibrosis is characterised by proliferation and fibrosis of retroperitoneal tissue. It is complicated by obstruction and encasement of retroperitoneal structures. CASE REPORT: We describe two female patients with idiopathic retroperitoneal fibrosis. Both had to undergo lateralization of the ureter because of ureteral obstruction. Also both patients developed thrombosis of the inferior vena cava resp. the common iliac vein. Because of the eventful course of the disease a combined tamoxifen and steroid therapy was started. Hereafter there was a marked regression of the retroperitoneal fibrotic masses and the previous inflammatory signs disappeared.
CONCLUSION: Tamoxifen seems to be effective in the treatment of idiopathic retroperitoneal fibrosis by inducing a regression of the fibrotic masses. Especially in patients with continuous activity of the disease we recommend an additional steroid therapy to prevent a regeneration of the fibrosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9324631     DOI: 10.1007/BF03042577

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  28 in total

1.  Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process.

Authors:  J K ORMOND
Journal:  J Urol       Date:  1948-06       Impact factor: 7.450

Review 2.  Idiopathic retroperitoneal fibrosis.

Authors:  H Lepor; P C Walsh
Journal:  J Urol       Date:  1979-07       Impact factor: 7.450

3.  Response of multicentric desmoid tumours to tamoxifen.

Authors:  H Procter; L Singh; M Baum; D Brinkley
Journal:  Br J Surg       Date:  1987-05       Impact factor: 6.939

4.  Alimentary complications of non-malignant retroperitoneal fibrosis.

Authors:  R J Mitchell
Journal:  Br J Surg       Date:  1971-04       Impact factor: 6.939

5.  Tamoxifen for retroperitoneal fibrosis.

Authors:  J R Benson; M Baum
Journal:  Lancet       Date:  1993-03-27       Impact factor: 79.321

6.  The association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature.

Authors:  G O Littlejohn; E C Keystone
Journal:  J Rheumatol       Date:  1981 Jul-Aug       Impact factor: 4.666

7.  Evidence that tamoxifen is a histamine antagonist.

Authors:  E A Kroeger; L J Brandes
Journal:  Biochem Biophys Res Commun       Date:  1985-09-16       Impact factor: 3.575

8.  Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity.

Authors:  K Horgan; E Cooke; M B Hallett; R E Mansel
Journal:  Biochem Pharmacol       Date:  1986-12-15       Impact factor: 5.858

9.  Treatment of idiopathic retroperitoneal fibrosis by immunosuppression.

Authors:  W S McDougal; R C MacDonell
Journal:  J Urol       Date:  1991-01       Impact factor: 7.450

10.  Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases.

Authors:  L R Baker; W J Mallinson; M C Gregory; E A Menzies; W R Cattell; H N Whitfield; W F Hendry; J E Wickham; A M Joekes
Journal:  Br J Urol       Date:  1987-12
View more
  1 in total

1.  Gender-based differences in bleomycin-induced pulmonary fibrosis.

Authors:  Mehrnaz Gharaee-Kermani; Kazuo Hatano; Yasuhiro Nozaki; Sem H Phan
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.